Does chemotherapy improve survival outcomes in breast cancer survivors with secondary primary stage I non-small cell lung cancer? A real-world analysis using machine learning models
SPLC with prior breast cancer do have a poorer prognosis than lung cancer patients, although postoperative chemotherapy can benefit some individuals, careful selection of patients to receive chemotherapy is still warranted. We developed COX-lung and MLP-lung models which can predict beneficiaries of chemotherapy, providing crucial insights for clinicians in formulating personalized treatment plans. The findings indicate that this patient population is heterogeneous, necessitating more individualized treatment strategies.
Authors
- Lutong Yan (ORCID: https://orcid.org/0000-0002-6398-8269)
- Xingzhuo Zhu
- Jiaqi Huang (ORCID: https://orcid.org/0000-0002-6514-3075)
- Bohao Liu (ORCID: https://orcid.org/0000-0003-1092-5341)
- Guangjian Zhang (ORCID: https://orcid.org/0000-0002-4540-8179)
- Na Hao (ORCID: https://orcid.org/0000-0002-7389-9825)
- Jinteng Feng (ORCID: https://orcid.org/0000-0002-1415-6423)
- Shan Gao (ORCID: https://orcid.org/0000-0001-9291-2442)
- Deqian Qiao
Institutions
- Fudan University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fonc.2025.1646580
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00